Daniel Lindholm

Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990-2023: a Global Burden of Disease study

Lee, Sooji; Lindholm, Daniel; Sundström, Johan; Yon, Dong Keon

Part of Nature Medicine, p. 1454-1478, 2026

• DOI for Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990-2023: a Global Burden of Disease study

A deep learning ECG model for identification and localization of occlusion myocardial infarction

Gustafsson, Stefan; Ribeiro, Antônio H.; Gedon, Daniel; Abreu, Petrus E. O. G. B. et al.

Part of Nature Communications, 2026

• DOI for A deep learning ECG model for identification and localization of occlusion myocardial infarction
• Download full text (pdf) of A deep learning ECG model for identification and localization of occlusion myocardial infarction

Cardiomyopathies: Nationwide Trends in Prevalence, Incidence, and Mortality (2004-2023)

Lindholm, Daniel; Ribom, Gustav; Gustafsson, Stefan; Pol, Tymon et al.

Part of Journal of the American College of Cardiology, p. 1087-1090, 2026

• DOI for Cardiomyopathies: Nationwide Trends in Prevalence, Incidence, and Mortality (2004-2023)

SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications

Eriksson, Jan W; Fanni, Giovanni; Lundqvist, Martin H.; Jansson, Stefan P. O. et al.

Part of Diabetes, obesity and metabolism, p. 1327-1338, 2026

• DOI for SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications
• Download full text (pdf) of SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications

Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023

Schumacher, Austin E; Lindholm, Daniel P; Murray, Christopher J L

Part of The Lancet, p. 1731-1810, 2025

• DOI for Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023
• Download full text (pdf) of Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023

Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990-2023: a Global Burden of Disease study

Lee, Sooji; Lindholm, Daniel; Sundström, Johan; Yon, Dong Keon

Part of Nature Medicine, p. 1454-1478, 2026

• DOI for Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990-2023: a Global Burden of Disease study

A deep learning ECG model for identification and localization of occlusion myocardial infarction

Gustafsson, Stefan; Ribeiro, Antônio H.; Gedon, Daniel; Abreu, Petrus E. O. G. B. et al.

Part of Nature Communications, 2026

• DOI for A deep learning ECG model for identification and localization of occlusion myocardial infarction
• Download full text (pdf) of A deep learning ECG model for identification and localization of occlusion myocardial infarction

Cardiomyopathies: Nationwide Trends in Prevalence, Incidence, and Mortality (2004-2023)

Lindholm, Daniel; Ribom, Gustav; Gustafsson, Stefan; Pol, Tymon et al.

Part of Journal of the American College of Cardiology, p. 1087-1090, 2026

• DOI for Cardiomyopathies: Nationwide Trends in Prevalence, Incidence, and Mortality (2004-2023)

SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications

Eriksson, Jan W; Fanni, Giovanni; Lundqvist, Martin H.; Jansson, Stefan P. O. et al.

Part of Diabetes, obesity and metabolism, p. 1327-1338, 2026

• DOI for SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications
• Download full text (pdf) of SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications

Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023

Schumacher, Austin E; Lindholm, Daniel P; Murray, Christopher J L

Part of The Lancet, p. 1731-1810, 2025

• DOI for Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023
• Download full text (pdf) of Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023

Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Hay, Simon I; Lindholm, Daniel P; Gakidou, Emmanuela

Part of The Lancet, p. 1873-1922, 2025

• DOI for Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
• Download full text (pdf) of Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023

Stark, Benjamin A.; Ahmed, Anisuddin; Lindholm, Daniel; Marks-Hultström, Michael et al.

Part of Journal of the American College of Cardiology, p. 2167-2243, 2025

• DOI for Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023
• Download full text (pdf) of Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

Mohsen, Naghavi; Sundström, Johan; Lindholm, Daniel P; Murray, Christopher J L

Part of The Lancet, p. 1811-1872, 2025

• DOI for Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023
• Download full text (pdf) of Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021

Kerr, Jessica A; Lindholm, Daniel P; Azzopardi, Peter S

Part of The Lancet, p. 785-812, 2025

• DOI for Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
• Download full text (pdf) of Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021

Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021

Steel, Nicholas; Lindholm, Daniel P; Newton, John N

Part of The Lancet Public Health, 2025

• DOI for Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021
• Download full text (pdf) of Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Naghavi, Mohsen; Kyu, Hmwe Hmwe; A, Bhoomadevi; Aalipour, Mohammad Amin et al.

Part of The Lancet, p. 1811-1872, 2025

• DOI for Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021

Ng, Marie; Lindholm, Daniel P; Vollset, S. E.

Part of The Lancet, p. 813-838, 2025

• DOI for Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
• Download full text (pdf) of Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021

Reply to 'The patterns and changes of heart failure treatment in the last years of life still need further study'

Sundström, Johan; Lindholm, Daniel P

Part of European Journal of Heart Failure, p. 180-181, 2025

• DOI for Reply to 'The patterns and changes of heart failure treatment in the last years of life still need further study'

Regional assessment of availability for transcatheter aortic valve implantation in Sweden: a long-term observational study

Nilsson, Konrad; Lindholm, Daniel; Backes, Jenny; Bjursten, Henrik et al.

Part of European Heart Journal - Quality of Care and Clinical Outcomes, p. 641-649, 2024

• DOI for Regional assessment of availability for transcatheter aortic valve implantation in Sweden: a long-term observational study
• Download full text (pdf) of Regional assessment of availability for transcatheter aortic valve implantation in Sweden: a long-term observational study

Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Feigin, Valery L; Abate, Melsew Dagne; Abate, Yohannes Habtegiorgis; Abd ElHafeez, Samar et al.

Part of Lancet Neurology, p. 973-1003, 2024

• DOI for Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Vollset, Stein Emil; Ababneh, Hazim S; Abate, Yohannes Habtegiorgis; Abbafati, Cristiana et al.

Part of The Lancet, p. 2204-2256, 2024

• DOI for Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Heart failure treatment in the last years of life: A nationwide study of 364 000 individuals

Sundström, Johan; Gustafsson, Stefan; Cars, Thomas; Lindholm, Daniel P

Part of European Journal of Heart Failure, p. 2443-2450, 2024

• DOI for Heart failure treatment in the last years of life: A nationwide study of 364 000 individuals
• Download full text (pdf) of Heart failure treatment in the last years of life: A nationwide study of 364 000 individuals

Impact of COVID-19 in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Enrolled in the DELIVER Trial

Bhatt, Ankeet S.; Kosiborod, Mikhail N.; Claggett, Brian L.; Miao, Zi Michael et al.

Part of European Journal of Heart Failure, p. 2177-2188, 2023

• DOI for Impact of COVID-19 in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Enrolled in the DELIVER Trial

The Maraca Plot: A Novel Visualization of Hierarchical Composite Endpoints.

Karpefors, Martin; Lindholm, Daniel; Gasparyan, Samvel B.

Part of Clinical Trials, p. 84-88, 2023

• DOI for The Maraca Plot: A Novel Visualization of Hierarchical Composite Endpoints.

Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.

Kosiborod, Mikhail N.; Bhatt, Ankeet S.; Claggett, Brian L.; Vaduganathan, Muthiah et al.

Part of Journal of the American College of Cardiology, p. 460-473, 2023

• DOI for Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.

Operational Challenges and Mitigation Measures during the COVID-19 Pandemic-Lessons from DELIVER.

Bhatt, Ankeet S.; Lindholm, Daniel; Nilsson, Ann; Zaozerska, Natalia et al.

Part of American Heart Journal, p. 133-140, 2023

• DOI for Operational Challenges and Mitigation Measures during the COVID-19 Pandemic-Lessons from DELIVER.

IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF.

Adamson, Carly; Welsh, Paul; Docherty, Kieran F.; de Boer, Rudolf A. et al.

Part of JACC. Heart failure, p. 291-304, 2023

• DOI for IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF.

Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction

Butt, Jawad H.; Dewan, Pooja; Merkely, Béla; Belohlávek, Jan et al.

Part of Annals of Internal Medicine, p. 820-830, 2022

• DOI for Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction

Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure

Vaduganathan, Muthiah; Claggett, Brian L.; Jhund, Pardeep; de Boer, Rudolf A. et al.

Part of Journal of the American College of Cardiology, p. 1775-1784, 2022

• DOI for Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure

Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure

Vaduganathan, Muthiah; Claggett, Brian L.; Jhund, Pardeep; de Boer, Rudolf A. et al.

Part of Journal of the American College of Cardiology, p. 1775-1784, 2022

• DOI for Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure

Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction

Butt, Jawad H.; Kondo, Toru; Jhund, Pardeep S.; Comin-Colet, Josep et al.

Part of Journal of the American College of Cardiology, p. 1705-1717, 2022

• DOI for Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction

Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Vaduganathan, Muthiah; Claggett, Brian L.; Jhund, Pardeep; de Boer, Rudolf A. et al.

Part of JAMA cardiology, p. 1259-1259, 2022

• DOI for Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

Ostrominski, John W.; Vaduganathan, Muthiah; Claggett, Brian L.; de Boer, Rudolf A. et al.

Part of European Journal of Heart Failure, p. 1892-1901, 2022

• DOI for Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

Dapagliflozin in Heart Failure with Improved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial.

Vardeny, Orly; Fang, James C.; Desai, Akshay S.; Jhund, Pardeep S. et al.

Part of Nature medicine, p. 2504-2511, 2022

• DOI for Dapagliflozin in Heart Failure with Improved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial.

Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: A Patient-Level, Pooled Meta-Analysis of DAPA-HF and DELIVER.

Jhund, Pardeep S.; Kondo, Toru; Butt, Jawad H.; Docherty, Kieran F. et al.

Part of Nature medicine, p. 1956-1964, 2022

• DOI for Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: A Patient-Level, Pooled Meta-Analysis of DAPA-HF and DELIVER.

Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.

Butt, Jawad H.; Kondo, Toru; Jhund, Pardeep S.; Comin-Colet, Josep et al.

Part of Journal of the American College of Cardiology, p. 1705-1717, 2022

• DOI for Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.

Dapagliflozin for Heart Failure According to Body Mass Index: The DELIVER Trial.

Adamson, Carly; Kondo, Toru; Jhund, Pardeep S.; de Boer, Rudolf A. et al.

Part of European Heart Journal, p. 4406-4417, 2022

• DOI for Dapagliflozin for Heart Failure According to Body Mass Index: The DELIVER Trial.

Dapagliflozin and New York Heart Association Functional Class in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial

Ostrominski, John W.; Vaduganathan, Muthiah; Claggett, Brian L.; de Boer, Rudolf A. et al.

Part of European Journal of Heart Failure, p. 1892-1901, 2022

• DOI for Dapagliflozin and New York Heart Association Functional Class in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial

Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.

Peikert, Alexander; Martinez, Felipe A.; Vaduganathan, Muthiah; Claggett, Brian L. et al.

Part of Circulation Heart Failure, 2022

• DOI for Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.

Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.

Cunningham, Jonathan W.; Vaduganathan, Muthiah; Claggett, Brian L.; Kulac, Ian J. et al.

Part of Journal of the American College of Cardiology, p. 1302-1310, 2022

• DOI for Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.

Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.

Docherty, Kieran F.; Simpson, Joanne; Jhund, Pardeep S.; Inzucchi, Silvio E. et al.

Part of JACC. Heart failure, p. 104-118, 2022

• DOI for Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.

Docherty, Kieran F.; Welsh, Paul; Verma, Subodh; De Boer, Rudolf A. et al.

Part of Circulation, p. 980-994, 2022

• DOI for Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.

Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.

Berg, David D.; Docherty, Kieran F.; Sattar, Naveed; Jarolim, Petr et al.

Part of Circulation, p. 158-169, 2022

• DOI for Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.

Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction: A Post Hoc Analysis of the DAPA- HF Trial

Butt, Jawad H.; Dewan, Pooja; Merkely, Bela; Belohlavek, Jan et al.

Part of Annals of Internal Medicine, p. 820-830, 2022

• DOI for Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction: A Post Hoc Analysis of the DAPA- HF Trial

Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.

Butt, Jawad H.; Jhund, Pardeep S.; Belohlavek, Jan; de Boer, Rudolf A. et al.

Part of Circulation, p. 1210-1224, 2022

• DOI for Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.

Liver Tests and Outcomes in Heart Failure with Reduced Ejection Fraction: Findings from DAPA-HF.

Adamson, Carly; Cowan, Lorna M.; de Boer, Rudolf A.; Diez, Mirta et al.

Part of European Journal of Heart Failure, p. 1856-1868, 2022

• DOI for Liver Tests and Outcomes in Heart Failure with Reduced Ejection Fraction: Findings from DAPA-HF.

Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction

Docherty, Kieran F.; Ogunniyi, Modele O.; Anand, Inder S.; Desai, Akshay S. et al.

Part of JACC. Heart failure, p. 52-64, 2022

• DOI for Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon, Scott D.; McMurray, John J. V.; Claggett, Brian; de Boer, Rudolf A. et al.

Part of New England Journal of Medicine, p. 1089-1098, 2022

• DOI for Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.

Solomon, Scott D.; Vaduganathan, Muthiah; Claggett, Brian L.; de Boer, Rudolf A. et al.

Part of JACC. Heart failure, p. 184-197, 2022

• DOI for Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.

Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Myhre, Peder L.; Vaduganathan, Muthiah; Claggett, Brian L.; Miao, Zi Michael et al.

Part of JACC. Heart failure, p. 902-913, 2022

• DOI for Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Dapagliflozin Reduces Uric Acid Concentration, an Independent Predictor of Adverse Outcomes in DAPA-HF

McDowell, Kirsty; Welsh, Paul; Docherty, Kieran F.; Morrow, David A. et al.

Part of European Journal of Heart Failure, p. 1066-1076, 2022

• DOI for Dapagliflozin Reduces Uric Acid Concentration, an Independent Predictor of Adverse Outcomes in DAPA-HF

Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure

Vaduganathan, Muthiah; Claggett, Brian L.; Jhund, Pardeep; de Boer, Rudolf A. et al.

Part of Journal of the American College of Cardiology, p. 1775-1784, 2022

• DOI for Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.

Butt, Jawad H.; Adamson, Carly; Docherty, Kieran F.; de Boer, Rudolf A. et al.

Part of Circulation Heart Failure, 2021

• DOI for Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.

Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: An Analysis of DAPA-HF.

Dewan, Pooja; Docherty, Kieran F.; Bengtsson, Olof; de Boer, Rudolf A. et al.

Part of European Journal of Heart Failure, p. 632-643, 2021

• DOI for Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: An Analysis of DAPA-HF.

Efficacy of Dapagliflozin in Heart Failure with Reduced Ejection Fraction According to Body Mass Index.

Adamson, Carly; Jhund, Pardeep S.; Docherty, Kieran F.; Belohlavek, Jan et al.

Part of European Journal of Heart Failure, p. 1662-1672, 2021

• DOI for Efficacy of Dapagliflozin in Heart Failure with Reduced Ejection Fraction According to Body Mass Index.

Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.

Butt, Jawad H.; Docherty, Kieran F.; Petrie, Mark C.; Schou, Morten et al.

Part of JAMA cardiology, p. 678-689, 2021

• DOI for Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.

Dapagliflozin in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Rationale and Design of the DELIVER Trial

Solomon, Scott D.; de Boer, Rudolf A.; DeMets, David; Hernandez, Adrian F. et al.

Part of European Journal of Heart Failure, p. 1217-1225, 2021

• DOI for Dapagliflozin in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Rationale and Design of the DELIVER Trial

Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.

Shen, Li; Kristensen, Soren Lund; Bengtsson, Olof; Bohm, Michael et al.

Part of JACC. Heart failure, p. 254-264, 2021

• DOI for Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA- HF.

Docherty, Kieran F.; Jhund, Pardeep S.; Anand, Inder; Bengtsson, Olof et al.

Part of Circulation, p. 1623-1632, 2020

• DOI for Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA- HF.

Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.

Solomon, Scott D.; Jhund, Pardeep S.; Claggett, Brian L.; Dewan, Pooja et al.

Part of JACC. Heart failure, p. 811-818, 2020

• DOI for Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.

Jackson, Alice M.; Dewan, Pooja; Anand, Inder S.; Belohlavek, Jan et al.

Part of Circulation, p. 1040-1054, 2020

• DOI for Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.

Kosiborod, Mikhail N.; Jhund, Pardeep S.; Docherty, Kieran F.; Diez, Mirta et al.

Part of Circulation, p. 90-99, 2020

• DOI for Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.

Combined association of key risk factors on ischaemic outcomes and bleeding in patients with myocardial infarction

Lindholm, Daniel; Sarno, Giovanna; Erlinge, David; Svennblad, Bodil et al.

Part of Heart, 2019

• DOI for Combined association of key risk factors on ischaemic outcomes and bleeding in patients with myocardial infarction

Assessing the Nationwide Impact of a Registry-Based Randomized Clinical Trial on Cardiovascular Practice The TASTE Trial in Perspective

Buccheri, Sergio; Sarno, Giovanna; Frobert, Ole; Gudnason, Thorarinn et al.

Part of Circulation. Cardiovascular Interventions, 2019

• DOI for Assessing the Nationwide Impact of a Registry-Based Randomized Clinical Trial on Cardiovascular Practice The TASTE Trial in Perspective

Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study

Jernberg, Tomas; Lindholm, Daniel P; Hasvold, Lars Pål; Svennblad, Bodil et al.

Part of BMJ Open, 2019

• DOI for Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study
• Download full text (pdf) of Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study

Factors associated with non-attendance at exercise-based cardiac rehabilitation

Borg, Sabina; Oberg, Birgitta; Leosdottir, Margret; Lindholm, Daniel et al.

Part of BMC Sports Science, Medicine and Rehabilitation, 2019

• DOI for Factors associated with non-attendance at exercise-based cardiac rehabilitation
• Download full text (pdf) of Factors associated with non-attendance at exercise-based cardiac rehabilitation

Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR)

Buccheri, Sergio; James, Stefan; Lindholm, Daniel; Frobert, Ole et al.

Part of European Heart Journal, p. 2607-2615, 2019

• DOI for Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR)
• Download full text (pdf) of Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR)

Subsequent Event Risk in Individuals With Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium

Patel, Riyaz S.; Tragante, Vinicius; Schmidt, Amand F.; McCubrey, Raymond O. et al.

Part of Circulation, 2019

• DOI for Subsequent Event Risk in Individuals With Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium
• Download full text (pdf) of Subsequent Event Risk in Individuals With Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium

Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data

Patel, Riyaz S.; Schmidt, Amand F.; Tragante, Vinicius; McCubrey, Raymond O. et al.

Part of Circulation, 2019

• DOI for Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data
• Download full text (pdf) of Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data

Normal radiological lymph node appearance in the thorax

Hansen, Tomas; Nilsson, M.; Lindholm, Daniel P; Sundström, Johan et al.

Part of Diseases of the esophagus, p. 1-6, 2019

• DOI for Normal radiological lymph node appearance in the thorax

Bioabsorbable polymer everolimus-eluting stents in patients with acute myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.

Buccheri, Sergio; Sarno, Giovanna; Lagerqvist, Bo; Olivecrona, Göran et al.

Part of EuroIntervention, 2018

• DOI for Bioabsorbable polymer everolimus-eluting stents in patients with acute myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.

Caffeine and incidence of dyspnea in patients treated with ticagrelor

Lindholm, Daniel; James, Stefan K; Andersson, Jonas; Braun, Oscar Ö et al.

Part of American Heart Journal, p. 141-143, 2018

• DOI for Caffeine and incidence of dyspnea in patients treated with ticagrelor

Bioimpedance and New-Onset Heart Failure: A Longitudinal Study of >500 000 Individuals From the General Population.

Lindholm, Daniel; Fukaya, Eri; Leeper, Nicholas J; Ingelsson, Erik

Part of Journal of the American Heart Association, 2018

• DOI for Bioimpedance and New-Onset Heart Failure: A Longitudinal Study of >500 000 Individuals From the General Population.
• Download full text (pdf) of Bioimpedance and New-Onset Heart Failure: A Longitudinal Study of >500 000 Individuals From the General Population.

Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke.

Rao, Abhiram S; Lindholm, Daniel; Rivas, Manuel A; Knowles, Joshua W et al.

Part of Circulation, 2018

• DOI for Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke.

Machine Learning For Improved Detection Of Myocardial Infarction In Patients Presenting With Chest Pain In The Emergency Department

Lindholm, Daniel; Holzmann, Martin

Part of Journal of the American College of Cardiology, p. 225-225, 2018

• DOI for Machine Learning For Improved Detection Of Myocardial Infarction In Patients Presenting With Chest Pain In The Emergency Department

Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study

Lindholm, Daniel P; James, Stefan K; Gabrysch, Katja; Storey, Robert F et al.

Part of JAMA cardiology, p. 1160-1166, 2018

• DOI for Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study

Clinical and Genetic Determinants of Varicose Veins Prospective, Community-Based Study of approximate to 500 000 Individuals

Fukaya, Eri; Flores, Alyssa M.; Lindholm, Daniel P; Gustafsson, Stefan et al.

Part of Circulation, p. 2869-2880, 2018

• DOI for Clinical and Genetic Determinants of Varicose Veins Prospective, Community-Based Study of approximate to 500 000 Individuals

Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

Sarno, Giovanna; Lagerqvist, Bo; Olivecrona, Göran; Varenhorst, Christoph et al.

Part of Catheterization and cardiovascular interventions, p. 881-887, 2017

• DOI for Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

New Method for Assessing the Effect of Driving Distance to Hospital Care: Using OpenStreetMap Routing in Cardiovascular Research

Lindholm, Daniel P; James, Stefan K; Lagerqvist, Bo; Hlatky, Mark A et al.

Part of Circulation. Cardiovascular Quality and Outcomes, 2017

• DOI for New Method for Assessing the Effect of Driving Distance to Hospital Care: Using OpenStreetMap Routing in Cardiovascular Research

Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease

Lindholm, Daniel; Lindbäck, Johan; Armstrong, Paul W.; Budaj, Andrzej et al.

Part of Journal of the American College of Cardiology, p. 813-826, 2017

• DOI for Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease

Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.

Lindholm, Daniel P; Hagström, Emil; James, Stefan K; Becker, Richard C et al.

Part of Journal of the American Heart Association, 2017

• DOI for Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
• Download full text (pdf) of Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.

Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome

Lindholm, Daniel P; James, Stefan K; Bertilsson, Maria; Becker, Richard C et al.

Part of Clinical Chemistry, p. 573-584, 2017

• DOI for Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome

Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome

Johansson, Åsa; Eriksson, Niclas; Lindholm, Daniel; Varenhorst, Christoph et al.

Part of Human Molecular Genetics, p. 1447-1456, 2016

• DOI for Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome

Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial

Velders, Matthijs A.; Wallentin, Lars; Becker, Richard C.; van Boven, Adrianus J. et al.

Part of American Heart Journal, p. 879-8890000000, 2015

• DOI for Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial
• Download full text (pdf) of Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial

Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr

Lindholm, Daniel; Storey, Robert F.; Christersson, Christina; Halvorsen, Sigrun et al.

Part of American Heart Journal, p. 465-470, 2015

• DOI for Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr

Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial

Lindholm, Daniel; Varenhorst, Christoph; Cannon, Christopher P.; Harrington, Robert A. et al.

Part of European Heart Journal, p. 2083-2093, 2014

• DOI for Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial
• Download full text (pdf) of Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial

Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

Wallentin, Lars; Lindholm, Daniel; Siegbahn, Agneta; Wernroth, Lisa et al.

Part of Circulation, p. 293-303, 2014

• DOI for Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids

Crona, Joakim; Fanola, Irina; Lindholm, Daniel P.; Antonodimitrakis, Pantelis et al.

Part of Neuroendocrinology, p. 151-155, 2013

• DOI for Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids

Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma

Lindholm, Daniel P; Eriksson, Barbro; Granberg, Dan

Part of Medical Oncology, p. 301-303, 2012

• DOI for Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma

Early diagnosis of acute coronary syndrome

Katus, Hugo; Ziegler, André; Ekinci, Okan; Giannitsis, Evangelos et al.

Part of European Heart Journal, p. 3049-3055, 2017

• DOI for Early diagnosis of acute coronary syndrome

Bioresorbable Stents in PCI

Lindholm, Daniel; James, Stefan

Part of Current Cardiology Reports, 2016

• DOI for Bioresorbable Stents in PCI

Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors

Lindholm, Daniel P; Öberg, Kjell

Part of Hormone and Metabolic Research, p. 832-837, 2011

• DOI for Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors

Platelet Inhibition, Revascularization, and Risk Prediction in Non-ST-elevation Acute Coronary Syndromes

Lindholm, Daniel

2015

• Download full text (pdf) of Platelet Inhibition, Revascularization, and Risk Prediction in Non-ST-elevation Acute Coronary Syndromes